Form 10-K NIOCORP DEVELOPMENTS For: Jun 30
http://archive.fast-edgar.com/20260925/AM2V4G2GZ22RHZZ2222N2ZYJ34TMZZ22N282
Filed on: September 25, 2026
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NioCorp Provides Preliminary Unaudited Financial Results for the Three-Month Period Ended September 30, 2026
- NioCorp Places 100% of Its Planned Critical Minerals Production Under Commercial Sales Agreements
- Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share